课题基金 / 基金详情

Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function

Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
项目 1:通过 CRISPR 筛选发现 CD8 和 CD4 细胞命运和功能的调节因子
批准号:
9523362
负责人:
Arlene H. Sharpe
金额:
$50.66万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Arlene H. Sharpe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Protective immunity to infectious pathogens requires the coordinated differentiation of CD8+ and CD4+ T cells. Increasingly powerful and systematic profiling of the transcriptional, epigenetic, and metabolic changes that occur during this differentiation has identified an immense catalog of genes and pathways that could play a role in regulating T cell differentiation in response to acute infection. The challenge is now to ascribe functions to each of the genes that have been identified as part of the broad reprogramming of cell state that occurs during CD8+ and CD4+ T cell differentiation. This proposal seeks to use loss-of-function Cas9/CRISPR-mediated genetic screens in vivo to systematically identify the critical genes that govern the differentiation of CD8+ and CD4+ T cells in response to acute infection. We have developed a genetic screening platform that uses pooled, in vivo CRISPR-mediated loss-of- function genetic screens to identify genes that positively or negatively regulate the development of effector and memory populations. We have already used this platform to conduct pooled libraries with sequencing-based deconvolution to test in parallel the function of over 100 genes in CD8+ T cells responding to acute infection. This proof-of-principle screen successfully recovered known positive and negative regulators of effector differentiation. Building on these initial studies, we now propose to extend this system to identify and validate regulators of T cell response to acute infection in mouse models and human cells in the following aims: Aim 1: Curate candidate regulators from scRNA-seq profiles of CD8+ and CD4+ T cells during acute infection using scRNA-seq profiles. We will use massively parallel single-cell RNA-seq to deeply profile antigen-specific CD8+ and CD4+ T cells during acute infection and use computation modeling (with Core B) to identify candidate regulators. From this rich dataset we will identify a set of potential regulatory molecules that will be screened in Aim 2. Aim 2: Perform pooled CRISPR screens to identify regulators of CD8+ and CD4+ fate and function. We will use pooled CRISPR/Cas9 mediated genetic screens to survey the function of thousands of genes in regulating differentiation of CD8+ and CD4+ T cells. We will screen using defined phenotypes that will uncover genes that: initiate and sustain effector and memory differentiation; guide to a memory fate commitment; govern lineage choice; or regulate the acquisition of specific patterns of cytokine secretion. Aim 3: Validate candidates that regulate CD8 and CD4 differentiation in mouse models and human T cells. To validate these candidate regulators we will use an extensive set of cellular immunological assays in vivo and in vitro to probe their function individually using genome editing or conventional knockouts where available. We will complement these studies with CRISPR/Cas9 mediated gene editing in primary CD8+ and CD4+ T cells from healthy human subjects to test whether their regulatory role is conserved in human T cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining regulators of immunity to acute infection using CRISPR screens
  • 批准号:
    10210502
  • 项目类别:
  • 资助金额:
    $10.99万
  • 财政年份:
    2020
  • 负责人:
    Arlene H. Sharpe
  • 依托单位:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
  • 批准号:
    10153453
  • 项目类别:
  • 资助金额:
    $38.06万
  • 财政年份:
    2018
  • 负责人:
    Arlene H. Sharpe
  • 依托单位:
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
  • 批准号:
    10343840
  • 项目类别:
  • 资助金额:
    $30.14万
  • 财政年份:
    2018
  • 负责人:
    Arlene H. Sharpe
  • 依托单位:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
  • 批准号:
    9906872
  • 项目类别:
  • 资助金额:
    $38.05万
  • 财政年份:
    2018
  • 负责人:
    Arlene H. Sharpe
  • 依托单位:
海外基金